Business of Biotech Shorts

  1. Ep. 257, Chapter 2: Miasma Theory's Stubborn Grip With Thomas Levenson 7/28/2025

    Historical misconceptions, particularly the concept of miasmas, hindered the acceptance of germ theory. Traditional ideas to explain the spread of disease centered on keeping the body's humors (or, later, chemical imbalances) in balance, Levenson explains. These ideas were metaphorically useful for describing disease, but they offered no specific treatments. Still, miasma theory’s enduring power lay in its descriptive utility. Observing a disease spreading, the idea of invisible "seeds" carried on the wind seemed like a plausible explanation, even if it didn't reveal the actual mechanism.

  2. Ep. 257, Chapter 1: Unpacking The Germ Theory Revolution With Thomas Levenson 7/28/2025

    Life Science Leader Chief Editor Ben Comer and science writer Thomas Levenson discuss the latter’s latest book, "So Very Small: How Humans Discovered the Microcosmos, Defeated Germs, and May Still Lose the War Against Infectious Diseases.” The book focuses on the 19th-century "germ theory revolution," particularly Robert Koch's 1876-1877 discovery of the anthrax bacillus as the pathogen causing anthrax.

  3. Ep. 256, Chapter 6: Biomarkers, Endpoints, And The Future of Psychedelic Therapies With Srinivas Rao 7/18/2025

    Dr. Srinivas Rao notes that validated biomarkers and regulatory endpoints for mental health conditions like depression would be transformative, however despite promising signs from psychedelic research, they have not yet been verified. He also discusses whether the hallucinatory aspect of psychedelics, i.e., the trip, is necessary, noting that the experience most likely plays a role in disrupting entrenched neural patterns and promoting neuroplasticity. Ultimately, he believes psychedelic therapies, especially short-duration ones, have the potential to reshape mental health treatment by offering rapid, effective relief.

  4. Ep. 256, Chapter 5: The atai Life Sciences Approach With Srinivas Rao 7/18/2025

    atai began with a broad hub-and-spoke model, combining internal drug development with strategic investments in Beckley Psytech and Recognify Life Sciences to diversify its pipeline and address unmet needs in mental health. After disappointing clinical results with their PCN-101 (R-ketamine) therapy, atai streamlined its operations to focus on fewer assets with high potential, particularly short-duration psychedelics that align with existing clinical infrastructure. Over the next year, the company anticipates four key Phase 2 readouts which will be critical in shaping its next phase of growth.

  5. Ep. 256, Chapter 4: Unique Challenges Of Psychedelic Development With Srinivas Rao 7/18/2025

    While Dr. Srinivas Rao views psychedelics as simply another class of pharmacological compounds, they carry cultural baggage that can complicate drug development. He acknowledges the stigma around substances like psilocybin and MDMA among some physicians and patients, especially those wary of their histories as illicit drugs. To address this, atai focuses on rigorous science, novel compounds with shorter durations to reduce patient anxiety, and physician education to shift perceptions over time.

  6. Ep. 256, Chapter 3: Successes And Failures In The Psychedelic Therapy Space With Srinivas Rao 7/18/2025

    Reflecting on his experience at other drug companies, Dr. Srinivas Rao emphasizes the importance of prioritizing patient-reported outcomes and starting with the end in mind. atai designed its VLS-01 compound to fit existing healthcare infrastructure and gained significant insight from the Spravato® path to market. Rao also discusses the Multidisciplinary Association for Psychedelic Studies’ (MAPS) failed attempt to gain FDA approval for its MDMA-assisted therapy due to non-standardized therapy protocols, unblinded trial designs, and inadequate trial size.

  7. Ep. 256, Chapter 2: The Investment Landscape Of Psychedelic Drug Development With Srinivas Rao 7/18/2025

    Dr. Srinivas Rao discusses the shifting investment landscape for psychedelic therapies. Momentum started to build following the 2019 approval of Spravato®, a form of ketamine used to treat depression. The COVID-19 pandemic brought a surge of biotech investments, fueling rapid growth in the psychedelic space, but that enthusiasm dwindled in late 2021 amid broader biotech downturns. Despite the challenges — regulatory obstacles, market volatility, and a cautious investor pool — promising assets can still attract funding.

  8. Ep. 256, Chapter 1: Introduction To Srinivas Rao And atai Life Sciences 7/18/2025

    Chief Editor of Life Science Leader and Host of The Business of Biotech, Ben Comer, and CEO of atai Life Sciences, Srinivas Rao, M.D., Ph.D., discuss how Rao’s early passion for building and problem-solving led him from electrical engineering to biomedical applications and eventually, to a combined MD/PhD path focused on brain science. In 2018, atai Life Sciences was founded with the intention of delivering psychedelics and other innovative treatments for mental health conditions.

  9. Ep. 255, Chapter 5: Global Dollars And Sense with Yaniv Sneor 7/11/2025

    Sneor clarifies that Mid Atlantic Bio Angels is agnostic to company location, investing across the US and internationally. While European and Asian syndicate partners often seek MAB Angels' investment in their opportunities, they are less inclined to invest in MAB Angels' portfolio companies — a disparity Sneor suggests stems from differences in startup environments, talent, and tolerance for failure across continents. Sneor also discusses his work as CEO of Native State Therapeutics, an early-stage company targeting protein misfolding neurodegenerative diseases like Parkinson's and Alzheimer's. He concludes by commenting upon the shakeup at NIH and FDA, which could influence pharma's R&D focus and ultimately affect MAB Angels' long-term investment strategies.

  10. Ep. 255, Chapter 4: Executable Exits with Yaniv Sneor 7/11/2025

    Sneor points out that that, while Mid Atlantic Bio Angels supports and guides their portfolio companies through liaisons, they do not drive exits; the biotech management teams are expected to possess or acquire that capability. Additionally, Sneor states that opportunities in "buzzy" therapeutic areas like GLP-1s face no less scrutiny. Future market landscape, the biotech’s timeline for acquisition, a robust patent estate and a unique value proposition all must be considered. MAB Angels rarely fills a round alone, but they only refer deals to syndicate partners once they have made an investment decision themselves, which serves as a strong endorsement.